Basic Information
MOUNJARO INJECTION 2.5MG/0.5ML
INJECTION, SOLUTION
Regulatory Information
SIN16716P
March 1, 2023
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
June 4, 2025
Company Information
DKSH SINGAPORE PTE. LTD.
DKSH SINGAPORE PTE. LTD.
Active Ingredients
Strength: 2.5mg/0.5mL
Detailed Information
Contraindications
**4 CONTRAINDICATIONS** MOUNJARO is contraindicated in patients with: - A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) _\[see Warnings and Precautions (5.1)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_. - Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO _\[see Warnings and Precautions (5.4)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_.
Indication Information
**1 INDICATIONS AND USAGE** MOUNJARO™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use - MOUNJARO has not been studied in patients with a history of pancreatitis _\[see Warnings and Precautions (5.2)_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ _\]_. - MOUNJARO is not indicated for use in patients with type 1 diabetes mellitus.